However, these pioneering therapies targeting HER2 have no clinical effect on the 80% of breast cancers that are devoid of HER2 amplification (formerly called “HER2 negative”), and including tumors expressing low levels of HER2 by IHC (1+ , or 2+ without gene amplification by FISH). The gene discussed is ERBB2; the disease is breast carcinoma.